{
    "2020-06-25": [
        [
            {
                "time": "2018-03-15",
                "original_text": "The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "LLY",
                        "ABBV",
                        "NBIX",
                        "RDY"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-24",
                "original_text": "Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine",
                "features": {
                    "keywords": [
                        "Alector",
                        "AL002",
                        "TREM2",
                        "Alzheimer’s Disease",
                        "Preclinical",
                        "Phase 1"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-07",
                "original_text": "Sosei, AbbVie sign drug discovery deal worth up to $1 billion",
                "features": {
                    "keywords": [
                        "Sosei",
                        "AbbVie",
                        "drug discovery",
                        "$1 billion"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}